Amit Munshi - 04 Dec 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: Director
Signature: /s/ Latha Vairavan, as Attorney-in-Fact for Amit Munshi
Issuer symbol: ARQT
Transactions as of: 04 Dec 2025
Transactions value $: $0
Form type: 4
Filing time: 08 Dec 2025, 20:02:58 UTC
Previous filing: 02 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Munshi Amit	Director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE	/s/ Latha Vairavan, as Attorney-in-Fact for Amit Munshi	08 Dec 2025	0001612551

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARQT	Common Stock	Award	$0	+2.02K	+101.05%	$0.00	4.02K	04 Dec 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARQT	Stock Option (right to buy)	Award	$0	+16.5K		$0.00	16.5K	04 Dec 2025	Common Stock	16.5K	$31.16	Direct	F2
transaction	ARQT	Stock Option (right to buy)	Award	$0	+6.18K		$0.00	6.18K	04 Dec 2025	Common Stock	6.18K	$31.16	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.
F2	1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of December 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.
F3	The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.